Search results
Found 80 matches for
Novel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.
PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer
19 May 2025
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointme…
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
5 May 2025
Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has…
Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs
30 April 2025
Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen® and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financia…
PepGen announces appointment of two new directors to its Board
30 March 2025
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointme…
Moa named one of TIME's top greentech companies in 2025
26 March 2025
Moa recognised as leading global innovator in environmental impact.
Moa forms new biological partnership with NAICONS
25 March 2025
Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
26 February 2025
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Bo…
Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen® biology and expression
18 February 2025
Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio’s pipeline of TCR-based immunotherapies targeting Dark Antigens®
Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025
22 January 2025
The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK. "This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develo…
Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
9 January 2025
The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.
Theolytics appoints David Apelian MD, PhD, MBA as CEO
17 December 2024
David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian…
OMass Therapeutics strengthens its leadership team with the promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical
6 December 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Lo…
Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer
19 November 2024
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with adva…
OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer
15 November 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlt…
CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture
10 November 2024
CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress towa…
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
21 October 2024
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.
Internationally renowned academic Lee Sweetlove joins Moa
15 October 2024
Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, w…
Moa’s groundbreaking science features in journal Weed Science
9 October 2024
Breaking the 30 year impasse in novel herbicide discovery.
Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
2 October 2024
Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, in…
OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2
30 September 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead progra…